<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106569</url>
  </required_header>
  <id_info>
    <org_study_id>1660190</org_study_id>
    <nct_id>NCT05106569</nct_id>
  </id_info>
  <brief_title>Telespirometry in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Home-Based Spirometry Through Telemedicine in Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mitsubishi Tanabe Pharma America Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators seek to validate Slow Vital Capacity (SVC) measurement in seated and supine&#xD;
      positions using conventional and portable spirometry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SVC is obtained with in-clinic conventional spirometry, in-clinic portable spirometry, and&#xD;
      in-home portable spirometry with respiratory therapist-supervised remote pulmonary function&#xD;
      testing every two weeks in a six month prospective study of participants with a diagnosis of&#xD;
      Amyotrophic Lateral Sclerosis. SVC decline over time, seated and supine, will be tracked with&#xD;
      assessments for treatment changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ALS Functional Rating Scale, Revised (ALS FRSR)</measure>
    <time_frame>2 week intervals for 6 months</time_frame>
    <description>Minimum 0, Maximum 48; Lower scores worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline SVC percent predicted at clinic</measure>
    <time_frame>3 months</time_frame>
    <description>SVC measured at clinic in seated and supine positions using conventional and portable spirometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline SVC percent predicted at clinic</measure>
    <time_frame>6 months</time_frame>
    <description>SVC measured at clinic in seated and supine positions using conventional and portable spirometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline SVC percent predicted at home</measure>
    <time_frame>2 week intervals for 6 months</time_frame>
    <description>SVC measured from home in seated and supine positions using portable spirometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Dyspnea in Amyotrophic Lateral Sclerosis 15 (DALS-15)</measure>
    <time_frame>2 week intervals for 6 months</time_frame>
    <description>Minimum 0, Maximum 30; Higher scores worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum 0, Maximum 42; Higher scores worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Amyotrophic Lateral Sclerosis Assessment Questionnaire-5 (ALSAQ-5) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum 0, Maximum 20; Higher scores worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen (ALS-CBCS)</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum 0, Maximum 20; Lower scores worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen (ALS-CBCS) ALS Caregiver Behavioral Questionnaire at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Minimum 0, Maximum 45; Lower scores worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Amyotrophic Lateral Sclerosis Treatment Questionnaire</measure>
    <time_frame>2 week intervals for 6 months</time_frame>
    <description>Reports usage of non-invasive ventilation, gastrostomy tube, ALS medications and ALS devices</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>SUNY Upstate</arm_group_label>
    <description>One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrium Health</arm_group_label>
    <description>One of 2 ALS certified treatment centers in USA expected to recruit 50 subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.</description>
    <arm_group_label>Atrium Health</arm_group_label>
    <arm_group_label>SUNY Upstate</arm_group_label>
    <other_name>Pulmonary Function Test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects are invited to volunteer and recruited from ALS specialty care outpatient clinics&#xD;
        at SUNY Upstate and Atrium Health.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of ALS as Clinically Possible, Clinically Probable, Laboratory-supported&#xD;
             Probable and Clinically Definite ALS&#xD;
&#xD;
          2. 18 years old to 100 years old, English-speaking ALS subjects, male and female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of non-invasive ventilation more than 16 hours daily&#xD;
&#xD;
          2. Non-English Speaker&#xD;
&#xD;
          3. Psychosis or severe mental illness&#xD;
&#xD;
          4. Use of high-dose sedating psychotropic medications determined to potentially interfere&#xD;
             with task performance&#xD;
&#xD;
          5. Infection Control issues and specific Pulmonary, Cardiac, Vascular contraindications&#xD;
             as listed in the Standardization of Spirometry 2019 Update (Graham 2019)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eufrosina Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Upstate</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SUNY Upstate</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Geronimo A, Simmons Z. Evaluation of remote pulmonary function testing in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):348-355. doi: 10.1080/21678421.2019.1587633. Epub 2019 Apr 7.</citation>
    <PMID>30957547</PMID>
  </reference>
  <reference>
    <citation>Hegewald MJ, Gallo HM, Wilson EL. Accuracy and Quality of Spirometry in Primary Care Offices. Ann Am Thorac Soc. 2016 Dec;13(12):2119-2124.</citation>
    <PMID>27598295</PMID>
  </reference>
  <reference>
    <citation>Couratier P, Vincent F, Torny F, Lacoste M, Melloni B, Lemaire F, Antonini MT. Spirometer-dependence of vital capacity in ALS: validation of a portable device in 52 patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Dec;6(4):239-45.</citation>
    <PMID>16319028</PMID>
  </reference>
  <reference>
    <citation>Masa JF, González MT, Pereira R, Mota M, Riesco JA, Corral J, Zamorano J, Rubio M, Teran J, Farré R. Validity of spirometry performed online. Eur Respir J. 2011 Apr;37(4):911-8. doi: 10.1183/09031936.00011510. Epub 2010 Jul 22.</citation>
    <PMID>20650985</PMID>
  </reference>
  <reference>
    <citation>Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.</citation>
    <PMID>31613151</PMID>
  </reference>
  <results_reference>
    <citation>Rutkove SB, Qi K, Shelton K, Liss J, Berisha V, Shefner JM. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):61-67. doi: 10.1080/21678421.2018.1541095. Epub 2018 Nov 28.</citation>
    <PMID>30486680</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Eufrosina I. Young</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pulmonary Function Test</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Slow Vital Capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share Individual Patient Data collected during the study to research team from both sites.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2 years.</ipd_time_frame>
    <ipd_access_criteria>Research team includes Principal investigators, sub-investigators, clinical research coordinators and respiratory therapists at each site, Pulmonologist Central Readers at SUNY Upstate. Deidentified data is shared with study sponsor MTPA.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

